Is AstraZeneca plc A Super Growth Stock?

Although in the midst of facing a vast patent cliff, could AstraZeneca plc (LON: AZN) still be viewed as a top growth stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2014 has been a great year for investors in AstraZeneca (LSE: AZN) (NYSE: AZN.US). Indeed, shares in the pharmaceutical stock are currently up 17% while the FTSE 100 is down around 1% year-to-date. However, as many investors are well aware, AstraZeneca is currently facing a major challenge: patent expiry and subsequent generic competition. Does this mean that it shouldn’t be viewed as a top growth stock? Or does AstraZeneca have strong long-term growth potential?

The Patent Cliff

As mentioned, AstraZeneca is experiencing a loss of patents on many of its blockbuster drugs, with generic competition causing revenues to fall significantly as a result. The impact on the company’s bottom-line has been savage, with AstraZeneca reporting a fall in earnings per share (EPS) of 6% in 2012 and a whopping 26% fall in 2013. Furthermore, the next couple of years are unlikely to see much of an improvement, as AstraZeneca’s EPS is forecast to fall by a further 14% this year and by 2% in 2015.

A Strong Pipeline

On the face of it, then, AstraZeneca does not look like a super growth stock. Indeed, over the next couple of years that is likely to be the case. However, AstraZeneca recently announced results that show its drug pipeline is going from strength to strength, with its oncology pipeline looking particularly strong as a result of Phase 2 trials that went well. As a result, AstraZeneca is moving ahead with Phase 3 trials in both drugs, and is also planning late-stage trials for two drugs that treat breathing disorders.

astrazenecaThis pipeline means that, while short-term growth may be lacking, AstraZeneca is well positioned to deliver longer-term growth for shareholders. An indication of the attractiveness of its prospects can be seen in rumours surrounding a possible £60 billion bid from Pfizer for the entire company. Clearly, AstraZeneca has potential.

Looking Ahead

Of course, such potential is unlikely to come cheap. However, AstraZeneca does not appear to be overly priced, with shares currently trading on a price to earnings (P/E) ratio of 14. This compares well with the FTSE 100, which has a P/E of 13.3. Indeed, although the short run may not be full of growth, the medium to long-term could prove to be a completely different story. With the market seemingly looking beyond the next two years, it seems as though AstraZeneca could continue to perform well and deserves to be described as a super (long-term) growth stock.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares in AstraZeneca.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »